PRIMOBOLAN
Mild DHT-derived anabolic steroid with low androgenic activity, used primarily in cutting cycles; available as oral acetate and injectable enanthate.
Methenolone was developed in the 1960s and studied clinically for postoperative recovery, urological diseases, and hepatopathy, with early German and Japanese literature documenting its anabolic and anti-catabolic effects. Metabolite identification studies have characterized its urinary excretion profile, with 3α-hydroxy-1-methylen-5α-androstan-17-one as the major metabolite detectable for up to 5 days after a single 10 mg oral dose. Despite its reputation as a 'mild' steroid, robust controlled trials in athletic populations are essentially absent, and most dosing and efficacy data come from anecdotal bodybuilding experience rather than rigorous clinical research. Its low rate of aromatization and reduced androgenic profile are well-established pharmacologically, but long-term safety data in performance contexts remain limited.